Key result
Paclitaxel chemotherapy successfully treated diffuse alveolar hemorrhage in a 70-year-old man with metastatic cardiac angiosarcoma.
Why the study?
Diffuse alveolar hemorrhage is rarely reported in association with metastatic angiosarcoma and may not be well-recognized by most clinicians.
Case Report (n=1)
Paclitaxel chemotherapy may be a beneficial and successful treatment for diffuse alveolar hemorrhage secondary to metastatic cardiac angiosarcoma, a condition that typically has an extremely grave prognosis.
Paclitaxel may be trialed in this rare, grave presentation; hypothesis-generating and requires prospective validation.
Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome caused by various etiologies. DAH has rarely been reported to be associated with metastatic angiosarcoma. However, due to the rarity of complications, it may not be well-recognized by most clinicians. Herein, we report the case of a 70-year-old man with newly diagnosed metastatic cardiac angiosarcoma presenting with DAH. After an immediate bronchoalveolar lavage study and bronchoscopic biopsy, the patient was successfully treated with paclitaxel chemotherapy. Although most patients with this phenomenon have an extremely grave prognosis in previous literature, our experience showed that appropriate evaluation and treatment may be beneficial.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) conducted a case report in Diffuse alveolar hemorrhage from metastatic cardiac angiosarcoma (n=1). Paclitaxel chemotherapy was evaluated on Successful treatment of diffuse alveolar hemorrhage. Paclitaxel chemotherapy successfully treated diffuse alveolar hemorrhage in a 70-year-old man with metastatic cardiac angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: